DNCB-induced skin inflammation was accompanied by increases in serum IgE and IL-4 levels, and gracillin co-treatment inhibited these DNCB-induced increases by 48.6% (Figure 6a) and 71.4% (Figure 6b), respectively. This evidence concerns the gene IL4 and dermatitis.